Jazz Pharmaceuticals' Two Ziihera Regimens Receive FDA Approval to Treat Adults With Unresectable Locally Advanced or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma

25 Aug 2026 · 14:02 UTC

Observed price moves

JAZZ+0.39%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.